Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse
| Autor: | Martin Johansson, Niklas Axén, Moustapha Hassan, Jian Liu, Ying Zhao, Stefan Grudén, Charlott Brunmark, Bo Holmqvist, Erwin D. Brenndörfer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Biodistribution
Fluorescence-lifetime imaging microscopy Mice Nude Pharmaceutical Science 02 engineering and technology Pharmacology Immunofluorescence 030226 pharmacology & pharmacy Fluorescence Mice 03 medical and health sciences 0302 clinical medicine Epidermal growth factor In vivo Cell Line Tumor medicine Animals Tissue Distribution Epidermal Growth Factor medicine.diagnostic_test Chemistry Biological activity 021001 nanoscience & nanotechnology Controlled release Drug delivery 0210 nano-technology hormones hormone substitutes and hormone antagonists |
| Zdroj: | International Journal of Pharmaceutics. 601:120588 |
| ISSN: | 0378-5173 |
| DOI: | 10.1016/j.ijpharm.2021.120588 |
| Popis: | Aim The study was designed to evaluate the ability of the calcium sulfate based NanoZolid® drug delivery technology to locally release the epidermal growth factor (EGF) protein while maintaining its biological activity. Methods NanoZolid-formulated EGF protein labelled with a near infrared dye (EGF-NIR) depots or EGF-NIR dissolved in PBS were injected subcutaneously into mice bearing EGF receptor (EGFR) positive human A549 lung cancer tumors inoculated subcutaneously. The release and biodistribution of the EGF-NIR were investigated in vivo longitudinally up to 96 h post administration, utilizing whole body fluorescence imaging. In order to confirm the in vivo findings, histological analysis of tumor cryosections was performed to investigate EGF-NIR fluorescent signal and EGFR expression level by immunofluorescence labelling. Results The in vivo fluorescence imaging showed a controlled release profile of the EGF-NIR loaded in the NanoZolid depots compared to free EGF-NIR. Histological analysis of the tumors further demonstrated a prevailing distribution of EGF-NIR in regions with high levels of EGFR expression. Conclusion Calcium sulfate based depots can be used to formulate EGF while maintaining its biological activity, e.g. receptor binding capability. This may have a good clinical potential for local delivery of biomolecules to enhance treatment efficacy and minimize systemic adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect